New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 1, 2014
13:07 EDTARIAARIAD presents updated Phase 1/2 data on AP26113
ARIAD Pharmaceuticals announced updated clinical results on its investigational tyrosine kinase inhibitor, TKI, AP26113, in patients with advanced non-small cell lung cancer, NSCLC, from an ongoing Phase 1/2 trial. These study results show anti-tumor activity of AP26113 in patients with crizotinib-resistant anaplastic lymphoma kinase, ALK, positive NSCLC, including patients with brain metastases. Crizotinib is approved for ALK-positive NSCLC patients. The updated Phase 1/2 results are being presented at the 2014 American Society of Clinical Oncology, ASCO, annual meeting in Chicago. “The data from the Phase 2 portion of the trial show that AP26113 exhibits anti-tumor activity in patients with crizotinib-resistant ALK rearranged NSCLC, as well as crizotinib-naïve ALK rearranged NSCLC,” stated Scott N. Gettinger, M.D., associate professor of medicine at Yale School of Medicine. “Importantly, AP26113 demonstrates activity against brain metastases in patients with prior crizotinib therapy, including responses of clinically meaningful duration.”
News For ARIA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 10, 2014
12:11 EDTARIAOptions with increasing implied volatility
Subscribe for More Information
09:00 EDTARIAOn The Fly: Pre-market Movers
Subscribe for More Information
07:46 EDTARIAARIAD announces PRAC of EMA recommends Iclusig for continued EU use
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use